We are live on ! Find out more
CLDI icon

Calidi Biotherapeutics
CLDI

42 hedge funds and large institutions have $204M invested in Calidi Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

5% more funds holding

Funds holding: 40 → 42 (+2)

1% more capital invested

Capital invested by funds: $202M → $204M (+$1.6M)

0.01% more ownership

Funds ownership: 0.74% → 0.75% (+0.01%)

Holders
42
Holders Change
+2
Holders Change %
+5%
% of All Funds
0.71%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
11
Reduced
7
Closed
3
Calls
$602K
Puts
–
Net Calls
+$602K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
Nomura Holdings
Nomura Holdings
Japan
+$7.44M
2
Millennium Management
Millennium Management
New York
+$5.47M
3
PAMP
Polar Asset Management Partners
Ontario, Canada
+$2.88M
4
SC
Sculptor Capital
New York
+$2.63M
5
Parallax Volatility Advisers
Parallax Volatility Advisers
California
+$2.52M

Top Sellers

Rank Fund Capital Flow
1
BCM
Beryl Capital Management
California
-$11.5M
2
AMH
Apollo Management Holdings
New York
-$7.42M
3
HCM
Highbridge Capital Management
New York
-$4.31M
4
PCM
Pinz Capital Management
New York
-$564K
5
PCM
Prelude Capital Management
New York
-$275K
Name Holding Trade Value Shares
Change 		Change in
Stake
Deutsche Bank
26
Deutsche Bank
Germany
$994K – – –
BFM
27
Boothbay Fund Management
New York
$860K -$7.14K -6 -0.8%
LA
28
Linden Advisors
New York
$497K – – –
AA
29
AQR Arbitrage
Connecticut
$403K – – –
EC
30
Elequin Capital
New York
$398K +$397K +333 New
KKRC
31
Kohlberg Kravis Roberts & Co
New York
$351K – – –
AI
32
Arena Investors
New York
$349K – – –
PCM
33
Prelude Capital Management
New York
$322K -$275K -231 -46%
SSA
34
Schonfeld Strategic Advisors
New York
$274K +$1.19K +1 +0.4%
OMC
35
Old Mission Capital
Illinois
$186K -$79.8K -67 -30%
DFCM
36
Dark Forest Capital Management
Puerto Rico
$20K – – –
UBS Group
37
UBS Group
Switzerland
$16K – – –
CCFM
38
Cohen & Co Financial Management
New York
$3K +$316K +265 New
CS
39
Clear Street
New York
$1K +$1.19K +1 New
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
$995 – – –
SCM
41
Segantii Capital Management
Hong Kong
$497 – – –
BCM
42
Beryl Capital Management
California
– -$11.5M -9,667 Closed
PCM
43
Pinz Capital Management
New York
– -$564K -475 Closed
CM
44
Cohanzick Management
New York
– -$25K -21 Closed
MF
45
Magnetar Financial
Illinois
– +$626K +526 New
1
2

CLDI Hedge Fund Activity: Q2 2022 in Review

42 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q2 2022, worth a combined $204M — up 0.79% from $202M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CLDI positions and 3 closed out — a net gain of 2 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Nomura Holdings, adding an estimated $7.44M. The largest seller was Beryl Capital Management, exiting entirely with an estimated $11.5M sold.

  • 42 institutional investors held Calidi Biotherapeutics (CLDI) as of Q2 2022, up from 40 in Q1 2022.
  • Funds reported $204M of Calidi Biotherapeutics stock for Q2 2022, up 0.79% quarter-over-quarter.
  • 5 funds opened new Calidi Biotherapeutics positions in Q2 2022 and 3 closed out, a net change of +2 holders.
  • The largest Calidi Biotherapeutics buyer in Q2 2022 was Nomura Holdings, an estimated $7.44M added.
  • The largest Calidi Biotherapeutics seller in Q2 2022 was Beryl Capital Management, an estimated $11.5M sold.

Based on aggregated 13F filings for Q2 2022.